Tecentriq (J9022): what insurers contract to pay

Atezolizumab · Hematology-Oncology

CareCost Research · Reviewed by Erin Rose

Tecentriq (J9022) carries a median commercial contracted rate of 98.2 on the Medicare ASP=100 index — 4.4% below the 102.7 typical-acquisition benchmark and 5.8% below the 104.3 Medicare payment line. 58 insurers report contracted rates across 52 states (1,020 priced cells), covering $459M in modeled Part B spend. It ranks #20 of 25 on the CareCost Buy-and-Bill Risk List, with a risk score of 68.3 out of 100.

Contracted rate range across insurers

Shaded band: 10th–90th percentile across insurers. Darker band: 25th–75th percentile. Solid tick: median. Dashed lines: 100 (Medicare ASP), 102.7 (typical acquisition cost), 104.3 (Medicare payment after sequestration).

What each insurer contracts to pay

All 50 insurers with published rates for this code, ranked highest to lowest. Index is a multiple of Medicare ASP (ASP=100).

Insurer	Index	vs. acquisition	Practices	States
BlueCross BlueShield of Nebraska	119.3	+16.2%	34	7
BlueCross BlueShield of South Carolina	117.5	+14.4%	55	6
Regence Idaho	111.4	+8.5%	45	6
Regence Utah	108.7	+5.8%	50	5
Regence BlueCross BlueShield	107.1	+4.3%	56	14
Regence Washington	107.0	+4.2%	75	5
BCBS North Dakota	105.5	+2.7%	139	3
BlueCross BlueShield of Arkansas	105.5	+2.7%	48	21
BlueCross BlueShield of Wyoming	105.1	+2.3%	44	7
Wellmark BCBS (Iowa/South Dakota)	103.5	+0.8%	78	10
Blue Cross NC	102.8	+0.1%	187	52
Blue Cross of Idaho	102.0	−0.7%	58	6
Aetna	101.5	−1.2%	584	51
Anthem Massachusetts	101.0	−1.7%	64	25
Capital Blue Cross	100.9	−1.8%	92	35
BlueCross BlueShield of Kansas	100.6	−2.0%	60	5
Blue Shield of California	100.6	−2.0%	124	4
Premera Blue Cross	99.6	−3.0%	103	9
Anthem California	99.6	−3.0%	64	4
BlueCross BlueShield of Minnesota	99.3	−3.3%	68	7
HMSA (BCBS Hawaii)	98.4	−4.2%	58	4
BlueCross BlueShield of Louisiana	98.4	−4.2%	54	7
BlueCross BlueShield of Texas	97.6	−5.0%	39	8
Anthem Kentucky	97.4	−5.2%	92	8
Anthem Missouri	97.4	−5.2%	39	11
UnitedHealthcare	97.4	−5.2%	1,080	51
Anthem Wisconsin	97.4	−5.2%	154	5
Harvard Pilgrim Health Care	97.4	−5.2%	229	10
BlueCross BlueShield of Massachusetts	97.4	−5.2%	43	4
Anthem New York	97.3	−5.3%	72	15
Anthem Nevada	97.3	−5.3%	194	4
Anthem Connecticut	97.3	−5.3%	66	5
BlueCross BlueShield of Alabama	97.3	−5.3%	91	6
Anthem Maine	97.3	−5.3%	65	5
Cigna	97.3	−5.3%	721	51
Kaiser Permanente	97.3	−5.3%	312	8
Regence Oregon	97.3	−5.3%	58	7
Anthem Indiana	97.3	−5.3%	136	25
Florida Blue	97.3	−5.3%	32	5
Anthem New Hampshire	97.3	−5.3%	49	7
Anthem Ohio	97.3	−5.3%	78	13
Anthem Georgia	97.3	−5.3%	64	16
CareFirst BlueCross BlueShield	97.3	−5.3%	58	19
Anthem Virginia	97.3	−5.3%	72	20
BlueCross BlueShield of Rhode Island	97.3	−5.3%	291	3
Centene	97.3	−5.3%	238	17
BlueCross BlueShield of Tennessee	94.6	−7.9%	61	10
BlueCross BlueShield of Michigan	94.2	−8.3%	63	7
Horizon BCBS of New Jersey	90.4	−12.0%	41	6
BlueCross BlueShield of Arizona	81.7	−20.4%	38	19

The price history

Medicare's payment limit for Tecentriq moved +18.1% between Q1 2022 and Q2 2026. Because contracted rates are set as a multiple of ASP, a rising denominator lifts every contracted rate tied to it.

Solid dots: finalized CMS ASP quarters. Hollow dots: preliminary. Values are the Medicare payment limit (ASP + 6%, pre-sequestration) per billing unit.

Part B utilization

Year	Part B spend	Dosage units (M)
2019	$464M	6.5
2020	$624M	8.7
2021	$656M	9.1
2022	$778M	9.8
2023	$755M	9.4
2024	$678M	—
2025	$459M	—

Where it pays most and least

Highest-paying states	Index	Insurers
Alaska (AK)	111.8	7
Idaho (ID)	106.9	12
Nebraska (NE)	105.5	9
Utah (UT)	105.1	12
Montana (MT)	104.6	6

Lowest-paying states	Index	Insurers
New York (NY)	97.3	22
Georgia (GA)	97.3	23
Tennessee (TN)	97.3	18
Massachusetts (MA)	97.3	18
Virginia (VA)	97.3	15

The Atezolizumab family

Code	Brand	Index	Insurers	Part B spend
J9024	Tecentriq Hybreza	98.6	53	$10M
J9022	Tecentriq	98.2	58	$459M

Within this family, Tecentriq Hybreza (J9024) contracts 0.4 points higher on the ASP=100 index than Tecentriq (J9022) — 98.6 vs. 98.2.

What this means in dollars

At the median contracted rate, this code models a −$4,345 shortfall per $100,000 of acquisition-benchmark drug cost purchased — illustrative modeled margin exposure, not a claim about any single practice's actual reimbursement.

Based on 1,020 priced contract cells across 58 insurers and 52 states. These are insurers' contracted rates from published machine-readable files — not amounts actually paid on a claim, and not a guarantee of coverage or reimbursement. CareCost Estimate Infusion Reimbursement Index, Issue 01 (Q2 2026), v2.0. CC-BY 4.0. A drug-specific acquisition estimate exists in our warehouse but derives from ASP itself, so we do not print it — the flat 102.7 ODACS benchmark is the honest comparator here.

See also: Darzalex Faspro · Truxima · Enhertu · report home · methodology